Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy.
Oncological Gastroenterology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
Int J Mol Sci. 2023 Feb 7;24(4):3290. doi: 10.3390/ijms24043290.
In this study, we aimed to assess the accuracy of the proposed novel, noninvasive serum DSC test in predicting the risk of gastric cancer before the use of upper endoscopy. To validate the DSC test, we enrolled two series of individuals living in Veneto and Friuli-Venezia Giulia, Italy (n = 53 and n = 113, respectively), who were referred for an endoscopy. The classification used for the DSC test to predict gastric cancer risk combines the coefficient of the patient's age and sex and serum pepsinogen I and II, gastrin 17, and anti- immunoglobulin G concentrations in two equations: Y1 and Y2. The coefficient of variables and the Y1 and Y2 cutoff points (>0.385 and >0.294, respectively) were extrapolated using regression analysis and an ROC curve analysis of two retrospective datasets (300 cases for the Y1 equation and 200 cases for the Y2 equation). The first dataset included individuals with autoimmune atrophic gastritis and first-degree relatives with gastric cancer; the second dataset included blood donors. Demographic data were collected; serum pepsinogen, gastrin G17, and anti- IgG concentrations were assayed using an automatic Maglumi system. Gastroscopies were performed by gastroenterologists using an Olympus video endoscope with detailed photographic documentation during examinations. Biopsies were taken at five standardized mucosa sites and were assessed by a pathologist for diagnosis. The accuracy of the DSC test in predicting neoplastic gastric lesions was estimated to be 74.657% (65%CI; 67.333% to 81.079%). The DSC test was found to be a useful, noninvasive, and simple approach to predicting gastric cancer risk in a population with a medium risk of developing gastric cancer.
在这项研究中，我们旨在评估新的非侵入性血清 DSC 试验在使用内窥镜检查之前预测胃癌风险的准确性。为了验证 DSC 试验，我们招募了居住在意大利威尼托和弗留利-威尼斯朱利亚地区的两个系列的个体（分别为 n = 53 和 n = 113），他们因内窥镜检查而就诊。用于预测胃癌风险的 DSC 试验分类结合了患者年龄和性别以及血清胃蛋白酶原 I 和 II、胃泌素 17 和抗免疫球蛋白 G 浓度的系数，共两个方程：Y1 和 Y2。使用回归分析和两个回顾性数据集（Y1 方程 300 例，Y2 方程 200 例）的 ROC 曲线分析，推断出变量系数和 Y1 和 Y2 截断值（分别为>0.385 和>0.294）。第一个数据集包括自身免疫性萎缩性胃炎患者和有胃癌一级亲属的个体；第二个数据集包括献血者。收集了人口统计学数据；使用自动 Maglumi 系统测定血清胃蛋白酶原、胃泌素 G17 和抗 IgG 浓度。由胃肠病学家使用奥林巴斯视频内窥镜进行内窥镜检查，并在检查过程中进行详细的摄影记录。在内窥镜检查时，在五个标准化的黏膜部位进行活检，并由病理学家进行诊断。DSC 试验预测肿瘤性胃病变的准确性估计为 74.657%（65%CI；67.333%至 81.079%）。DSC 试验被发现是一种有用、非侵入性且简单的方法，可以预测具有中等胃癌发病风险人群的胃癌风险。
